Last $6.41 USD
Change Today +0.06 / 0.94%
Volume 2.9K
CPIX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 10:02 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

cumberland pharmaceuticals (CPIX) Snapshot

Open
$6.40
Previous Close
$6.35
Day High
$6.41
Day Low
$6.29
52 Week High
03/2/15 - $6.46
52 Week Low
05/8/14 - $4.20
Market Cap
111.3M
Average Volume 10 Days
24.8K
EPS TTM
$0.02
Shares Outstanding
17.4M
EX-Date
--
P/E TM
320.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for CUMBERLAND PHARMACEUTICALS (CPIX)

cumberland pharmaceuticals (CPIX) Related Bloomberg News

View More Bloomberg News

cumberland pharmaceuticals (CPIX) Related Businessweek News

No Related Businessweek News Found

cumberland pharmaceuticals (CPIX) Details

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

96 Employees
Last Reported Date: 03/11/14
Founded in 1999

cumberland pharmaceuticals (CPIX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $620.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $297.0K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $392.3K
Chief Commercial Officer, Senior Vice Preside...
Total Annual Compensation: $312.1K
Chief Compliance Officer and Vice President o...
Total Annual Compensation: $227.5K
Compensation as of Fiscal Year 2013.

cumberland pharmaceuticals (CPIX) Key Developments

Cumberland Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 03, 2015

Cumberland Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 03, 2015

Cumberland Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Cumberland Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 03, 2015

Cumberland Pharmaceuticals Announces Pipeline Expansion with Boxaban™ (Ifetroban) Oral Capsule

Cumberland Pharmaceuticals Inc. announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD). Cumberland has completed manufacturing and received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) submission and Phase II study associated with the product. Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad, is a respiratory disease involving chronic asthma and nasal polyposis that is worsened by aspirin or nonsteroidal anti-inflammatory drugs. Approximately one in 20 asthmatic adults (nearly 1 million patients in the United States) suffer from AERD and the disease awareness is growing within the medical community. AERD is characterized by sharp increases in inflammatory mediators and platelet activity within the respiratory system. Ifetroban, an active thromboxane receptor antagonist, may interfere with these pathways to modify the disease and provide symptom relief. Current treatment of AERD remains a challenge, as novel and effective treatment modalities are lacking for this unmet medical need.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPIX:US $6.41 USD +0.06

CPIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $48.94 USD -4.77
Durect Corp $1.21 USD +0.18
Ironwood Pharmaceuticals Inc $15.70 USD -0.17
Pacira Pharmaceuticals Inc/DE $89.76 USD -2.55
Sucampo Pharmaceuticals Inc $14.15 USD +0.55
View Industry Companies
 

Industry Analysis

CPIX

Industry Average

Valuation CPIX Industry Range
Price/Earnings 100.0x
Price/Sales 3.0x
Price/Book 1.3x
Price/Cash Flow 65.5x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUMBERLAND PHARMACEUTICALS, please visit www.cumberlandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.